Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



GEN News Highlights

Back to Item »

Biogen Idec Takes Over Development of Hemophilia Therapies in Deal with Swedish Orphan Biovitrum

Biogen gains extended commercial rights and is now responsible for all activities and costs.

Forward this item to a colleague:
Your name
Your email
(Separate multiple addresses by commas)
 
Colleague's email
(Separate multiple addresses by commas)
 
Personal Message
(optional)
 
 
 

GEN Poll

More » Poll Results » Archive »

Myriad Genetics Trial: Your Thoughts?

Do you agree with the Supreme Court’s decision in the Myriad case?

Suggest a Poll